| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.06 | 0.06 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.06 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.06 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.076 | 0.06 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.06 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.07 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.07 |